Investigation Overview
An investigation on behalf of investors, who currently hold shares of ARMO BioSciences, Inc. (NASDAQ: ARMO), was announced concerning whether the takeover of ARMO BioSciences, Inc. by Eli Lilly and Company for $50.00 per share is unfair to NASDAQ: ARMO stockholders. The investigation by a law firm concerns whether certain officers and directors of ARMO BioSciences, Inc. breached thei...
You must register (for free) or login to view the entire investigation.